GeneTex
  • Country / Location Selection

United States (US)

BCMA Peptide

Cat No. GTX26087

Application

Neutralizing/Inhibition

Species

Human
Package
50 μg ($139)

APPLICATION

Application Note

The peptide is used for blocking the antibody activity of anti-BCMA (catalog no. GTX25972). It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37ºC.

PROPERTIES

Form

Liquid

Buffer

PBS pH7.2, 10mM NaH₂PO₄, 10mM Na₂HPO₄, 130mM NaCl, 0.1% BSA

Preservative

0.02% Sodium azide

Storage

Store the peptide at -20ºC, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

TARGET

Synonyms

Tnf Receptor Superfamily Member 17 , Bcm , Bcma , Cd269 , Tnfrsf13A , Tnfrsf17

Background

Members in the TNF superfamily regulate immune responses and induce apoptosis. Two novel members in the TNF family were recently identified and designated BAFF/BLyS/TALL-1/THANK/zTNF4 and April/TALL-2, respectively. BAFF was characterized as a B cell activator since it induced B cell proliferation and immunoglobulin secretion. April regulates immunological and non immunological cell growth. Three receptors, BCMA (for B cell maturation protein), TACI, and BAFF-R, for BAFF were recently identified. BCMA, like TACI, binds BAFF and April. BAFF and its receptors induce B cell development and survival, activate NF-kappaB and c-jun N-terminal kinase, and are involved in B cell associated autoimmune diseases.

Research Area

REFERENCE

There are currently no references for BCMA Peptide (GTX26087). Be the first to share your publications with this product.

REVIEW

There are currently no reviews for BCMA Peptide (GTX26087). Be the first to share your experience with this product.
SDS
PBS.pdf
Sodium Azide.pdf
Package List Price ($)
$ 139